PAIN
Volume 138, Issue 3 , Pages 657-666 , 15 September 2008

A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy

Received 22 May 2007 ,Revised 1 April 2008 ,Accepted 24 April 2008.

References 

  1. Argov Z, Steiner I, Soffer D. The yield of sural nerve biopsy in the evaluation of peripheral neuropathies. Acta Neurol Scand. 1989;79:243–245
  2. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3–S11
  3. Backonja MM, Galer BS. Pain assessment and evaluation of patients who have neuropathic pain. Neurol Clin. 1998;16:775–790
  4. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149–158
  5. Boivie J. Central pain. In:  Merskey H,  Loeser JD,  Dubner R editor. The paths of pain. Seattle, WA: IASP Press; 2005;p. 299–307
  6. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36
  7. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe. Prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333
  8. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care. 2002;25:2048–2052
  9. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother. 2006;40:251–260
  10. Campbell JN, Raja SN, Meyer RA, MacKinnon SE. Myelinated afferents signal the hyperalgesia associated with nerve injury. Pain. 1988;32:89–94
  11. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77–92
  12. Chen H, Lamer TJ, Rho RH, Marshall KA, Sitzman BT, Ghazi SM, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc. 2004;79:1533–1545
  13. Collins SD, Chessell IP. Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005;10:95–108
  14. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J. 1995;310:452–454
  15. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976–982
  16. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981;10:222–226
  17. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O’Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8:590–596
  18. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet. 1999;354:1248–1252
  19. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334
  20. Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother. 2005;5:823–830
  21. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7:892–900
  22. Harstall C, Ospina M. Prevalence of chronic pain. In:  Carr D editors. Clinical updates. vol. 11:Seattle, WA: IASP Press; 2003;p. 2
  23. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005;6:379–384
  24. Horowitz SH. Criteria for the diagnosis of peripheral neuropathies. Occup Environ Med. 2002;59:425–426
  25. Hughes RA. Peripheral neuropathy. BMJ. 2002;324:466–469
  26. Koike H, Mori K, Misu K, Hattori N, Ito H, Hirayama M, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology. 2001;56:1727–1732
  27. Martyn CN, Hughes RAC. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310–318
  28. Merskey H, Bogduk N. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Seattle, WA: IASP Press; 1994;p. 209–213
  29. Moalem-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy. Brain Behav Immun 2006 [Epub ahead of print].
  30. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931–1937
  31. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain – consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13–21
  32. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin Ther. 2004;26:951–979
  33. Notermans NC, Wokke JHJ, Van der Graaf Y, Franssen H, Van Dijk GW, Jennekens FGI. Chronic idiopathic axonal polyneuropathy: a five year follow up. J Neurol Neurosurg Psychiatry. 1994;57:1525–1527
  34. Notermans NC, Wokke JH, Franssen H, van der Graaf Y, Vermeulen M, van den Berg LH, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993;56:1066–1071
  35. Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, et al. Gabapentin for the treatment of pain in Guillain–Barre syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719–1723
  36. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250–256
  37. Prineas J. Polyneuropathies of undetermined cause. Acta Neurol Scand Suppl. 1970;44:3–72
  38. Rudolph T, Farbu E. Hospital-referred polyneuropathies – causes, prevalences, clinical and neurophysiological findings. Eur J Neurol. 2007;14:603–608
  39. Scadding JW, Koltzenburg M. Painful peripheral neuropathies. In:  McMahon SB,  Koltzenburg M editor. Wall and Melzack’s textbook of pain. London: Elsevier; 2006;p. 973–999
  40. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med. 2003;20:88–98
  41. Taylor R. Epidemiology of refractory neuropathic pain. Pain Pract. 2006;6:22–26
  42. Torebjork H, Lundberg L, LaMotte R. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol (Lond). 1992;448:765–780
  43. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281–289
  44. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology 2007 [Epub ahead of print].
  45. Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S. Peripheral neuropathy in young–old and old–old patients. Muscle Nerve. 2001;24:1476–1481
  46. Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS, et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol. 1999;56:540–547

☆ All coauthors have seen and agree with the contents of the manuscript. The authors have no financial interests to disclose.

PII: S0304-3959(08)00228-5

doi: 10.1016/j.pain.2008.04.023

PAIN
Volume 138, Issue 3 , Pages 657-666 , 15 September 2008

Article Tools

* Image Usage & Resolution